Mark Morrison, who joins as COO, was previously with Novartis and had global and regional leadership roles based in Switzerland (Basel) and Indonesia (Jakarta). As a Global Brand Director Mark led global launches for Cardiovascular and Respiratory innovative pharmaceuticals. Within the Asia – Middle East – Africa region Mark was Franchise Head for the Primary Care Business and then, following this role, became COO for Novartis, Indonesia during which time he led and drove several launches and a major business restructure. Mark’s appointment as COO will further strengthen the capabilities of the GPI team to anticipate and fully understand the challenges and opportunities faced by their highly-valued biopharmaceutical clients when launching treatment innovations globally.
GPI is also pleased to announce that Henrike Granzow is joining the GPI family as Associate Director, Pricing. In this role, Henrike will lead and further develop GPI’s innovative capabilities within pricing analytics and consultancy. She brings a wealth of experience across biopharmaceutical commercialization covering pricing, market access, HEOR, and finance. Henrike joins GPI from ICON where she was a member of the senior leadership team for pricing and market access. Prior to joining ICON, Henrike held positions of increasing seniority with Deerfield Management where she was responsible for planning and managing research projects on pricing, reimbursement and regulatory due diligence within the healthcare investment arena. Henrike holds a BA in Economics from University College, Dublin and an MSc in International Health Policy and Health Economics from the London School of Economics.
Preeti Patel, CEO said, “I am really pleased that Mark and Henrike are joining the GPI team. Mark will add International Pharma industry know-how and experience whilst Henrike will further deepen GPI’s pricing expertise and knowledge base. This strengthening of, and investment in, the GPI team will enable us to provide even better service to our valued biopharmaceutical clients. Preeti also added “GPI continues to support innovation for the pharmaceutical and biotechnology industry. These appointments strengthen our capabilities and our ability to stay ahead of our competitors whilst continuing to deliver best-in-class innovation for our clients.”
Mark stated: “I am very excited to be joining GPI and to have an opportunity to further build the team and our operational capabilities. I know from my extensive Pharma Industry experience that price and access are the dominant drivers of launch success. I am very pleased to be able to contribute to further innovation within this field – for both GPI’s clients and patients – by joining GPI as COO.”
Henrike stated: “GPI is perfectly positioned to add tremendous value for Pharma and Biotech clients through its unique combination of Pharma pricing and access expertise, intelligence, and data analytics power. From here we can grow our bespoke and innovative consultancy services which are underpinned and strengthened by the GPI pulse data and analytics platform. I am delighted to be able to join GPI at this exciting time and so contribute to the next stage of the growth phase.”
Global Pricing Innovations (GPI) is a market leader in business intelligence, analytics and innovative solutions for the life science industry. GPI supports pricing decisions and strategies through a combination of robust data-driven insights and bespoke analytical solutions, helping companies achieve operational improvement and market access excellence. GPI tools and services optimize clients’ price and value understanding for pre-and post-launch decision making.
As a global company, GPI has operating units and service partners throughout the world. GPI (www.globalpricing.com) is a privately held company headquartered in London, UK. For more information contact GPI at firstname.lastname@example.org or visit http://www.globalpricing.com or call: +44 (0) 203 874 3050